SEC Comment Letter for Item 9 Labs Corp. (INLB) (CIK 0001500123) — Feb 8, 2022
Item 9 Labs Corp. (INLB) (CIK 0001500123)
Date: Feb. 8, 2022 · CIK: 0001500123 · Accession: 0000000000-22-001535
AI Filing Summary & Sentiment
File numbers found in text: 024-11795
Letter
United States securities and exchange commission logo February 8, 2022 Robert Mikkelsen Chief Financial Officer Item 9 Labs Corp. 2727 N 3rd Street, Suite 201 Phoenix, AZ 85004 Re:Item 9 Labs Corp. Offering Statement on Form 1-A Filed February 2, 2022 File No. 024-11795 Dear Mr. Mikkelsen: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Jane Park at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Philip Magri, Esq.
Show Raw Text
United States securities and exchange commission logo
February 8, 2022
Robert Mikkelsen
Chief Financial Officer
Item 9 Labs Corp.
2727 N 3rd Street, Suite 201
Phoenix, AZ 85004
Re:Item 9 Labs Corp.
Offering Statement on Form 1-A
Filed February 2, 2022
File No. 024-11795
Dear Mr. Mikkelsen:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Jane Park at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Philip Magri, Esq.